Press Release – New York, NY – April 14, 2022 – Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: “RLMD”), a late-stage biotechnology company, in a …
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $172.5 Million Upsized Public Offering Underwritten by Goldman Sachs and Jefferies
Press Release – New York, NY – December 14, 2021 – Sichenzia Ross Ference LLP today announced that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company …
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $75 Million At-The-Market Offering
Press Release – New York, NY – May 26, 2020 – Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: “RLMD”), a clinical stage company developing therapies …
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common Stock
Press Release – New York, NY – December 6, 2019 – Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a clinical stage company developing …
Sichenzia Ross Ference LLP to Join Client Relmada Therapeutics, Inc. at Nasdaq Opening Bell Ringing
Press Release – New York, NY – October 15, 2019 – Sichenzia Ross Ference LLP founding partner Gregory Sichenzia will join representatives of client Relmada Therapeutics, Inc. (Nasdaq: RLMD), a …
Sichenzia Ross Ference LLP Congratulates Relmada Therapeutics, Inc., on NASDAQ Uplisting
New York, NY – October 10, 2019 – Sichenzia Ross Ference LLP announced today that the firm represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), in the Company’s up-listing to the NASDAQ Capital …
